Data from: Small RNA sequencing reveals a novel tsRNA-26576 mediating tumorigenesis of breast cancer

Purpose: As a malignancy that develops from breast tissue, breast cancer
has been widely regarded as the most common type of cancer threatening the
health of women worldwide. Emerging evidence has demonstrated that tsRNAs
might play a vital part in the tumorigenesis and progression of several
types of cancers. However, the functions of tsRNAs in breast cancer remain
largely unknown. Here, we investigated the functions of tsRNA-26576 in
tumorigenesis of breast cancer. Patients and methods: In this study, the
tsRNA deregulation states in breast cancer patients (four cancer tissues
and four adjacent normal tissues) were evaluated using small RNA
sequencing. And then, RT-PCR was used to detected the tsRNA-26576
expression level in breast cancer patients. Results: A total of 263 tsRNAs
were identified as significantly differentially expressed, of which 75
were upregulated, and 188 were downregulated. The functional
classification through KEGG pathway database illustrated that the most
significant pathway enriched by the targets of differentially expressed
tsRNAs was the pathway in cancer. Among these differently expressed
tsRNAs, we found that tsRNA-26576 was remarkably upregulated in cancer
tissue in comparison with adjacent normal tissue. Meanwhile, RT-PCR
results verified that tsRNA-26576 expression level was highly upregulated
in 10 paired samples from breast cancer patients. Besides, tsRNA-26576 was
found to motivate cellular multiplication and migration while suppressing
cellular apoptosis in MDA-MB-231 cells. Moreover, mRNA sequencing results
showed that several tumor suppressor genes, including FAT4 and SPEN, were
upregulated after delivering tsRNA-26576 inhibitor in MDA-MB-231 cells.
Conclusion: We found tsRNA-26576 was upregulated in breast cancer tissue,
and it could promote the cell growth while inhibite cell apoptosis.
Therefore, tsRNA-26576 might serve as a potential clinical therapy target
and a predictive marker for breast cancer.